Cancer Stem Cells

Cancer stem cells (CSCs), also known as tumor initiation cells (TICs), are undifferentiated cancer cells that can self-renew and differentiate into bulk tumor cells. They are thought to have a role in the resistance of tumors to therapy, and for disease recurrence.

Products
Background
Literature
Cat No Product Name / Activity
5802 A37
ALDH1A1 inhibitor; disrupts spheroid formation of ovarian cancer cells
5336 BRD 7116
Inhibitor of leukemia stem cell activity
6103 CD133-A15, 5'-DY647
High affinity fluorescently tagged aptamer for CD133 (AC133 epitope)
6104 CD133-B19, 5'-DY647
High affinity fluorescently tagged aptamer for CD133 (extracellular domain epitope)
1623 Cyclopamine
Inhibitor of Hedgehog (Hh) signaling; depletes stem-like cancer cells in glioblastoma
6102 Ep23, 5'-DY647
High affinity fluorescently tagged aptamer for EpCAM
1368 Geldanamycin
Selective Hsp90 inhibitor; breast cancer stem cell inhibitor
1803 ITE
Induces stem-like cancer cell differentiation; also inhibits TGF-beta -induced human myofibroblast differentiation
5727 MC 1742
Induces CSC apoptosis; also stimulates CSC osteogenic differentiation
4829 ML 239
Breast cancer stem cell inhibitor
5522 Napabucasin
Blocks cancer stem cell self-renewal; STAT3 inhibitor
4079 Niclosamide
Inhibits AML stem cells; STAT3 and mTORC1 signaling inhibitor
4189 SC 26196
Selective Δ6 desaturase inhibitor; eliminates cancer stem cells from ovarian cancer cell lines
5207 STF 118804
Depletes leukemia stem cells; NAMPT inhibitor
3070 Thioridazine hydrochloride
Selective inducer of CSC differentiation; anticancer agent
5960 TMI 1
Selectively cytotoxic towards CSCs
5328 TY 52156
Inhibits S1P-induced breast cancer stem cell expansion; S1P3 receptor antagonist
5305 Verteporfin
Suppresses cancer stem cell properties; YAP inhibitor
6111 Zoledronic Acid
Inhibits breast cancer cell renewal via inactivation of NF-κB; also potent FPP synthase inhibitor

Cancer stem cells (CSCs), also known as tumor initiation cells (TICs), are undifferentiated cancer cells that can self-renew and differentiate into bulk tumor cells. They are highly tumorigenic and are thought to be responsible, in some circumstances, for the resistance of tumors to chemo- and radiotherapy, as well as for disease recurrence following treatment. CSCs possess several characteristics that enable them to resist cancer therapies, including a slow cell cycle, resistance to oxidative stress, the ability to rapidly repair DNA damage and the capacity to expel anticancer drugs.

The origin of CSCs is unclear; they may derive from normal stem or progenitor cells or other cancer cells. Self-renewal of CSCs is through asymmetric division, by which one daughter cell retains the ability to self-renew, while the other will differentiate. CSC self-renewal and maintenance are regulated by various signaling pathways, including Notch, Hedgehog and Wnt, and these pathways are potential targets for new cancer therapies aimed at the elimination of CSCs and the prevention of relapse.

Literature for Cancer Stem Cells

Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Stem Cells

Stem Cells Scientific Review

Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.